Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

FRESENIUS KABI USA, LLC

Filed by CGCN GROUP, LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 19, 2026
Income
$50,000.00
Expenses
Not reported
Registrant
CGCN GROUP, LLC
Filing UUID
aeec4f67-12d0-422e-b7d7-c9c188e3c0de
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MAN · Manufacturing

Buy America legislation, tariffs, and tax incentives.

TAR · Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices.

TAX · Taxation/Internal Revenue Code

U.S. manufacturing incentives.

TRD · Trade (domestic/foreign)

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.